Cancer Prevention Research:每天一根香蕉,能让癌症远离?

2022-08-06 王聪 “生物世界”公众号

这项对近1000名林奇综合征患者的双盲对照试验显示,平均服用2年时间抗性淀粉作为膳食补充剂(服用剂量相当于每天吃一根香蕉),将林奇综合征患者患结直肠癌以外的癌症风险降低了一半以上,尤其是上消化道癌症。

林奇综合征(Lynch syndrome),是一种常染色体显性遗传的家族性肿瘤综合征,由于错配修复基因(mis-match repair,MMR)突变所致,造成DNA复制过程中的错误无法得到修复,从而被积累和遗传给后代,从而增加多种癌症风险,特别是结直肠癌,以及子宫内膜癌、卵巢癌、胃癌、食道癌、胰腺癌、胆道癌、脑肿瘤、皮肤癌等等。

近日,英国纽卡斯尔大学和利兹大学的研究人员在 Cancer Prevention Research 期刊发表了题为:Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up 的研究论文。

这项对近1000名林奇综合征患者的双盲对照试验显示,平均服用2年时间抗性淀粉作为膳食补充剂(服用剂量相当于每天吃一根香蕉),将林奇综合征患者患结直肠癌以外的癌症风险降低了一半以上,尤其是上消化道癌症(包括食道癌、胃癌、胆道癌、胰腺癌和十二指肠癌等),这种预防效果在停止服用补充剂后还能持续10年以上。

该研究的领导者、纽卡斯尔大学 John Mathers 教授表示,这项研究发现抗性淀粉可将林奇综合征患者的一系列癌症风险降低60%以上。这种效果在肠道上部最为明显,而上消化道癌症很难诊断,通常不会及早发现,因此这项研究显得非常重要。

抗性淀粉(resistant starch),又称抗酶解淀粉、难消化淀粉,在小肠中不能被酶解,但在大肠中可以与挥发性脂肪酸起发酵反应。抗性淀粉广泛存在于多种天然食品中,例如燕麦、马铃薯、大米、豌豆等豆类、略带绿色的香蕉等等。

与普通淀粉相比,抗性淀粉具有多种健康益处和更少的热量。该研究中使用的抗性淀粉被做成粉末补充剂,服用剂量相当于每天吃一根香蕉。抗性淀粉不会在小肠中被消化,而是进入大肠中发酵,为有益的肠道细菌提供营养,改变细菌的胆汁酸代谢,从而减少癌症发展。

从1999年到2005年,研究团队招募了近1000名林奇综合征患者,让他们在两年时间里每天服用粉末形式的抗性淀粉或阿司匹林或安慰剂。在治疗结束时,服用抗性淀粉或阿司匹林的林奇综合征患者与服用安慰剂的患者之间没有明显差异。但在随后的长达10年随访中,研究团队发现,服用抗性淀粉或阿司匹林显着降低了林奇综合征患者的癌症发病率。

其中,服用阿司匹林2年的林奇综合征患者的结直肠癌发病率降低了一半。这部分研究结果于2020年发表于《柳叶刀》。

总的来说,这两项临床试验表明,林奇综合征这种可遗传的癌症的发病风险是可预防的,

林奇综合征患者具有高癌症发病风险,而这两项临床试验表明,这种遗传性癌症是可预防的,服用阿司匹林能够降低一半林奇综合征患者的结直肠癌风险,而服用抗性淀粉则可以降低超过一半结直肠癌以外的其他癌症发病风险。

研究团队表示,目前正在进行一项更大规模的临床试验,共招募了1800多名临期综合征患者参与,以进一步确定是否能以更小、更安全的剂量的阿司匹林帮助降低林奇综合征患者的癌症发病风险。

原始出处:

John C. Mathers, et al. Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up. Cancer Prev Res (Phila) OF1–OF12.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2052379, encodeId=ae6520523e920, content=<a href='/topic/show?id=aeece1137b' target=_blank style='color:#2F92EE;'>#event#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7113, encryptionId=aeece1137b, topicName=event)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Fri Aug 19 16:53:00 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007820, encodeId=10f1200e820b0, content=<a href='/topic/show?id=421d14663a6' target=_blank style='color:#2F92EE;'>#prevention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14663, encryptionId=421d14663a6, topicName=prevention)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Tue Dec 20 08:53:00 CST 2022, time=2022-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557884, encodeId=0f4c155e88472, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Mon Aug 08 05:53:00 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236982, encodeId=b56812369826d, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sat Aug 06 20:14:08 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236965, encodeId=be381236965dd, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKgrnf67D3ddbalXADDrBnicULYYIn4tjz2jTiagbqHqFntDkYCVkE7WnVnz26n6XXUk4hTmFR8iczDQ/132, createdBy=4e9f5263713, createdName=cyfguvgi, createdTime=Sat Aug 06 19:14:43 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
    2022-08-19 lhlxtx
  2. [GetPortalCommentsPageByObjectIdResponse(id=2052379, encodeId=ae6520523e920, content=<a href='/topic/show?id=aeece1137b' target=_blank style='color:#2F92EE;'>#event#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7113, encryptionId=aeece1137b, topicName=event)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Fri Aug 19 16:53:00 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007820, encodeId=10f1200e820b0, content=<a href='/topic/show?id=421d14663a6' target=_blank style='color:#2F92EE;'>#prevention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14663, encryptionId=421d14663a6, topicName=prevention)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Tue Dec 20 08:53:00 CST 2022, time=2022-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557884, encodeId=0f4c155e88472, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Mon Aug 08 05:53:00 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236982, encodeId=b56812369826d, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sat Aug 06 20:14:08 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236965, encodeId=be381236965dd, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKgrnf67D3ddbalXADDrBnicULYYIn4tjz2jTiagbqHqFntDkYCVkE7WnVnz26n6XXUk4hTmFR8iczDQ/132, createdBy=4e9f5263713, createdName=cyfguvgi, createdTime=Sat Aug 06 19:14:43 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2052379, encodeId=ae6520523e920, content=<a href='/topic/show?id=aeece1137b' target=_blank style='color:#2F92EE;'>#event#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7113, encryptionId=aeece1137b, topicName=event)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Fri Aug 19 16:53:00 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007820, encodeId=10f1200e820b0, content=<a href='/topic/show?id=421d14663a6' target=_blank style='color:#2F92EE;'>#prevention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14663, encryptionId=421d14663a6, topicName=prevention)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Tue Dec 20 08:53:00 CST 2022, time=2022-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557884, encodeId=0f4c155e88472, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Mon Aug 08 05:53:00 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236982, encodeId=b56812369826d, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sat Aug 06 20:14:08 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236965, encodeId=be381236965dd, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKgrnf67D3ddbalXADDrBnicULYYIn4tjz2jTiagbqHqFntDkYCVkE7WnVnz26n6XXUk4hTmFR8iczDQ/132, createdBy=4e9f5263713, createdName=cyfguvgi, createdTime=Sat Aug 06 19:14:43 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
    2022-08-08 yangshch
  4. [GetPortalCommentsPageByObjectIdResponse(id=2052379, encodeId=ae6520523e920, content=<a href='/topic/show?id=aeece1137b' target=_blank style='color:#2F92EE;'>#event#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7113, encryptionId=aeece1137b, topicName=event)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Fri Aug 19 16:53:00 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007820, encodeId=10f1200e820b0, content=<a href='/topic/show?id=421d14663a6' target=_blank style='color:#2F92EE;'>#prevention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14663, encryptionId=421d14663a6, topicName=prevention)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Tue Dec 20 08:53:00 CST 2022, time=2022-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557884, encodeId=0f4c155e88472, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Mon Aug 08 05:53:00 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236982, encodeId=b56812369826d, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sat Aug 06 20:14:08 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236965, encodeId=be381236965dd, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKgrnf67D3ddbalXADDrBnicULYYIn4tjz2jTiagbqHqFntDkYCVkE7WnVnz26n6XXUk4hTmFR8iczDQ/132, createdBy=4e9f5263713, createdName=cyfguvgi, createdTime=Sat Aug 06 19:14:43 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
    2022-08-06 医鸣惊人

    认真学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2052379, encodeId=ae6520523e920, content=<a href='/topic/show?id=aeece1137b' target=_blank style='color:#2F92EE;'>#event#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7113, encryptionId=aeece1137b, topicName=event)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Fri Aug 19 16:53:00 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007820, encodeId=10f1200e820b0, content=<a href='/topic/show?id=421d14663a6' target=_blank style='color:#2F92EE;'>#prevention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14663, encryptionId=421d14663a6, topicName=prevention)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Tue Dec 20 08:53:00 CST 2022, time=2022-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557884, encodeId=0f4c155e88472, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Mon Aug 08 05:53:00 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236982, encodeId=b56812369826d, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sat Aug 06 20:14:08 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236965, encodeId=be381236965dd, content=,, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKgrnf67D3ddbalXADDrBnicULYYIn4tjz2jTiagbqHqFntDkYCVkE7WnVnz26n6XXUk4hTmFR8iczDQ/132, createdBy=4e9f5263713, createdName=cyfguvgi, createdTime=Sat Aug 06 19:14:43 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
    2022-08-06 cyfguvgi

    0

相关资讯

35万人研究:当“周末战士”靠谱吗?照样降低全因、癌症、CVD死亡风险!只要......

JAMA Intern Med:“周末战士”和其他休闲时间身体活动模式与全因和特定原因死亡率的关联全国范围的队列研究。

Science:癌症纳米医学新突破,大规模筛选揭示决定纳米颗粒递送效率的基因组因素

虽然使用纳米颗粒作为载体递送抗癌药物是治疗癌症有潜力的方式,还能避免化疗导致的副作用,但到目前为止,只有少数基于纳米颗粒的抗癌药物获得FDA批准上市。

Molecular Therapy : 关闭EBAG9基因,增强CAR-T效果

对于患有淋巴瘤、多发性骨髓瘤或白血病的癌症患者而言,嵌合抗原受体T细胞(CAR-T)治疗可能是他们战胜癌症的最后机会。通过提取患者自身的T细胞并在体外基因工程改造和扩增后回输到患者体内,这些CAR-T

Nature子刊:“垃圾”DNA会通过抑制DNA复制从而导致癌症!

所谓的非编码DNA实际上在细胞中发挥着重要且潜在的破坏性作用,它会阻断DNA复制并可能会打开癌变的大门。

把细菌改造为微型机器人,在磁场导航下精准递送药物,用于癌症治疗

细菌会被化学梯度所吸引,例如低氧水平或高酸度环境,而这两种情况普遍存在于肿瘤组织附近。在肿瘤组织附近注射细菌来治疗癌症被称为细菌介导的肿瘤治疗。细菌会向肿瘤组织中富集,并在肿瘤组织中生长,从而激活患者

著名癌症生物学家、miRNA研究领军人物因实验室学术不端被处罚

多年以来,Carlo Croce 实验室却一直面临着论文剽窃和伪造图像的指控,到目前为止,他参与的论文中,已经有11篇论文撤稿,另外还有21篇论文更正。